Clearmind Medicine Inc.
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” oregon the "Company"), a biotech institution focused connected find and improvement of caller psychedelic-derived therapeutics to lick large undertreated wellness problems, contiguous announced the initiation of objective batches of accumulation of its caller psychedelic-derived cause candidate, the MEAI- based molecule- CMND-100.
The produced batches volition beryllium utilized successful the Company's upcoming archetypal successful quality (FIH) objective proceedings evaluating the proprietary cause campaigner compound CMND-100 for the attraction of Alcohol Use Disorder (AUD).
Following MEAI's synthesis improvement process, the compound is being produced nether GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The objective batches accumulation is made imaginable owed to anterior palmy accumulation of MEAI cause substance that was utilized successful the Company's pre- objective studies designed to measure the information of its innovative compound.
"Clearmind continues its advancement toward FIH objective trial" said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. "This milestone joins different achievements we've made successful a comparatively abbreviated period. Non-clinical information generated to date, show that our MEAI- based attraction has the imaginable to dainty wide scope of addictions and binge behaviors specified arsenic AUD."
"Like different addictions, AUD is simply a chronic relapsing encephalon upset characterized by an impaired quality to halt oregon power intoxicant use," she added. "Alcohol maltreatment is the 3rd most-common preventable origin of decease successful the United States, wherever astir 6% conflict with this condition. "
The Company antecedently denote that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") gathering with the U.S. Food and Drug Administration ("FDA") to sermon the improvement of CMND-100.
About Clearmind Medicine Inc.
Clearmind is simply a psychedelic pharmaceutical biotech institution focused connected the find and improvement of caller psychedelic-derived therapeutics to lick wide and underserved wellness problems, including intoxicant usage disorder. Its superior nonsubjective is to probe and make psychedelic-based compounds and effort to commercialize them arsenic regulated medicines, foods oregon supplements.
The Company’s intelligence portfolio presently consists of 7 patent families. The Company intends to question further patents for its compounds whenever warranted and volition stay opportunistic regarding the acquisition of further intelligence spot to physique its portfolio.
Shares of Clearmind are listed for trading connected Nasdaq nether the awesome "CMND", the Canadian Securities Exchange nether the awesome "CMND" and the Frankfurt Stock Exchange nether the awesome “CWY”.
For further information, delight contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This property merchandise contains “forward-looking statements” wrong the meaning of the Private Securities Litigation Reform Act and different securities laws. Words specified arsenic “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and akin expressions oregon variations of specified words are intended to place forward-looking statements. For example, the Company is utilizing forward-looking statements erstwhile it discusses objective batches accumulation of its caller psychedelic-derived cause candidate, the Company's upcoming FIH objective trial, and immoderate aboriginal correspondence with the FDA. Forward-looking statements are not humanities facts, and are based upon management’s existent expectations, beliefs and projections, galore of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed successful bully faith. However, determination tin beryllium nary assurance that management’s expectations, beliefs and projections volition beryllium achieved, and existent results whitethorn disagree materially from what is expressed successful oregon indicated by the forward-looking statements. Forward-looking statements are taxable to risks and uncertainties that could origin existent show oregon results to disagree materially from those expressed successful the forward-looking statements. For a much elaborate statement of the risks and uncertainties affecting the Company, notation is made to the Company’s reports filed from clip to clip with the Securities and Exchange Commission (“SEC”), including, but not constricted to, the risks elaborate successful the Company’s last prospectus (registration No. 333-265900) filed with the SEC connected November 16, 2022. Forward-looking statements talk lone arsenic of the day the statements are made. The Company assumes nary work to update forward-looking statements to bespeak existent results, consequent events oregon circumstances, changes successful assumptions oregon changes successful different factors affecting forward-looking accusation but to the grade required by applicable securities laws. If the Company does update 1 oregon much forward-looking statements, nary inference should beryllium drawn that the Company volition marque further updates with respect thereto oregon with respect to different forward-looking statements. References and links to websites person been provided arsenic a convenience, and the accusation contained connected specified websites is not incorporated by notation into this property release. Clearmind is not liable for the contents of third-party websites.
English (US)